What is MitoSense?
MitoSense is an R&D enterprise focused on pioneering technology to replenish mitochondria, a critical cellular component. The company exclusively utilizes licensed and patent-pending innovations aimed at combating a spectrum of diseases, with a particular emphasis on neurodegenerative disorders. Its research targets debilitating conditions such as Amyotrophic Lateral Sclerosis (ALS), Alzheimers disease, and Parkinsons disease. Based in Plymouth, MA., MitoSense is positioned at the forefront of mitochondrial research for therapeutic applications.
How much funding has MitoSense raised?
MitoSense has raised a total of $3.5M across 1 funding round:
Angel/Seed
$3.5M
Angel/Seed (2024): $3.5M with participation from Caydan Capital Partners
Key Investors in MitoSense
Caydan Capital Partners
Caydan Capital Partners is an investment firm that participated in this funding round. Their specific investment focus is not detailed, but their involvement suggests a strategic interest in the biotechnology or R&D sector.
What's next for MitoSense?
The recent major strategic investment signals a pivotal moment for MitoSense, likely enabling the company to accelerate its research and development pipeline. This capital infusion is expected to fuel further scientific exploration, potentially leading to expanded clinical trials and the advancement of its proprietary technologies. The enterprise-level funding context suggests a focus on scaling operations and solidifying its market position in the competitive biotechnology sector.
See full MitoSense company page
